Key result
Phenprocoumon led to better quality of anticoagulation than acenocoumarol, with a higher time in therapeutic range (46.6% vs 41.6%; difference 5.0%, 95% CI 1.3-8.6%).
Why the study?
Does phenprocoumon improve the quality of anticoagulation compared to acenocoumarol in patients requiring oral anticoagulant therapy?
Population
456 patients from the Leiden anticoagulation clinic treated between 1998 and 1999 for more than 16 weeks…
Comparison
Phenprocoumon (long-acting oral anticoagulant, t… vs Acenocoumarol (short-acting oral anticoagulant…
Design
Cohort
Follow-up
more than 16 weeks (total 230 patient-years)
Authors
Loading...
May support phenprocoumon preference in VKA therapy; leaves open randomized confirmation of clinical outcomes.
Cohort (n=456)
No
Does phenprocoumon improve the quality of anticoagulation compared to acenocoumarol in patients requiring oral anticoagulant therapy?
Mean Difference: 5 (95% CI 1.3–8.6)
Absolute Event Rate: 46.6% vs 41.6%
The long-acting anticoagulant phenprocoumon provides better quality of anticoagulation (time in therapeutic range) than the short-acting acenocoumarol, with similar rates of major bleeding.
Gadisseur et al. (2002) conducted a cohort in Indication for oral anticoagulant therapy (n=456). Phenprocoumon vs. Acenocoumarol was evaluated on Time in therapeutic range (Difference 5.0%, 95% CI 1.3-8.6). Phenprocoumon led to better quality of anticoagulation than acenocoumarol, with a higher time in therapeutic range (46.6% vs 41.6%; difference 5.0%, 95% CI 1.3-8.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: